The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec ... so it should not be used by patients with a personal or family history ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections ... the cost of these new drugs, which have not yet been made public.

Hikma said on Monday it was “pleased to have FDA approval to launch this important medicine and to provide broader access and greater affordability for the patients who rely on it”.

The U.S. Food and Drug Administration has approved Zepbound (tirzepatide ... alongside significant weight loss. The FDA cautions that Zepbound is not without potential side effects.

Sleep apnea “occurs when a person’s upper airway becomes blocked, causing pauses in breathing during sleep,” per the FDA. “Today’s approval ... apnea treatment is not an option for ...

The U.S. Food and Drug Administration (FDA) has approved a generic daily injectable ... and multiple endocrine neoplasia syndrome Type 2 not to take the medication due to possible complications.

Advertisement "Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Dr. Sally Seymour of the FDA's Center ... adults are not at a healthy ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology conditions, including psoriatic arthritis and inflammatory bowel disease.

The Food and Drug Administration announced late Friday that it has approved Zepbound to ... diet and physical activity, the FDA said. Eli Lilly, the maker of Zepbound, stated that the drug was ...

The FDA has granted accelerated approval to zenocutuzumab ... so patients should confirm they’re not pregnant and use contraception during treatment and for two months afterward.